Xeris Biopharma Holdings (STU:2B30) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2B30 Xeris Biopharma Holdings Inc STU:2B30
74 GF Score
Price €7.23
GF Value €4.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Xeris Biopharma Holdings Valuation Rank Related Terms

STU:2B30
74GF Score
Xeris Biopharma Holdings Inc STU:2B30
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Xeris Biopharma Holdings (STU:2B30) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of €7.23 is trading 58.9% above its estimated GF Value™ of €4.55. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for STU:2B30:

  • Valuation Rank:
  • GF Value™: €4.55 vs. price of €7.23 (58.9% above fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the STU:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges XERS:USA0A8E:UK
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score

Get the complete analysis for STU:2B30

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.23
Price
€4.55
GF Value